Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.
Clin Exp Rheumatol. 2014 May-Jun;32(3):415-23. Epub 2014 Jan 20.
This is a review of the pharmacology of certolizumab pegol and its efficacy and safety in the treatment of patients with rheumatoid arthritis refractory to synthetic disease-modifying anti-rheumatic drugs (DMARDs). Certolizumab is a new anti-TNF-α biologic agent injected subcutaneously with an innovative molecular structure and unique pharmacodynamic and pharmacokinetic properties. Data from controlled clinical trials indicate that the drug is effective in reducing disease activity and disability. It also inhibits radiographic progression. Certolizumab administration has an acceptable safety profile. The clinical data available suggest that the nature of adverse events is generally comparable to that of other TNF-α blockers. Given its rapid onset of action certolizumab presents an attractive alternative therapeutic option for patients with moderate to severe RA refractory to DMARDs.
这是一篇关于培塞丽珠（certolizumab pegol）的药理学综述，以及其在治疗对合成疾病修饰抗风湿药物（DMARDs）反应不佳的类风湿关节炎患者中的疗效和安全性。培塞丽珠是一种新型的抗 TNF-α 生物制剂，皮下注射，具有创新性的分子结构和独特的药效学和药代动力学特性。来自对照临床试验的数据表明，该药可有效降低疾病活动度和残疾程度，还可抑制影像学进展。培塞丽珠的应用具有可接受的安全性特征。现有临床数据表明，不良事件的性质通常与其他 TNF-α 阻滞剂相似。鉴于其起效迅速，培塞丽珠为对 DMARDs 反应不佳的中重度 RA 患者提供了一种有吸引力的治疗选择。
